Pivoting toward neuromuscular diseases and Duchenne, Entrada locks down $116M crossover round
A little over two years since its last $59 million round, Entrada Therapeutics is making some more noise Wednesday with a nine-figure crossover. And they’ve got a new focus on neuromuscular diseases, led by Duchenne muscular dystrophy, as their research has broadened over the years.
Entrada pulled in a $116 million Series B, with the funds primarily slated for getting its first Duchenne program into the clinic. The Boston-based biotech hopes to get past the IND acceptance phase for the lead candidate and then expand into other neuromuscular areas.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.